Studies in muscle-invasive bladder cancer found ctDNA predicted metastatic risk after bladder-sparing treatment, while urine tumor DNA was more sensitive for residual bladder disease. Data from RETAIN-2 and a PNAS study support molecular testing to help select patients for bladder preservation.
Ultrasensitive testing of tumor DNA in blood and urine may identify muscle-invasive bladder cancer patients who can safely forgo radical cystectomy, with 69% achieving 3-year bladder-intact survival after systemic therapy.
A 30-year-old female with stage IV gallbladder adenocarcinoma achieved complete metabolic resolution of metastases after three cycles of pembrolizumab, gemcitabine, and cisplatin, despite presenting without traditional risk factors.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594431 |
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07583914 |
Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07537946 |
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07521826 |
Exercise Training in Women With Metastatic Breast Cancer |
NOT_YET_RECRUITING | NA |
| NCT07291895 |
High Dose Radiotherapy for Palliation (Hi-D) |
NOT_YET_RECRUITING | NA |
| NCT07176312 |
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients |
RECRUITING | PHASE2 |
| NCT07018505 |
EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers |
NOT_YET_RECRUITING | |
| NCT06937281 |
SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors |
NOT_YET_RECRUITING | NA |
| NCT06713161 |
Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status |
RECRUITING | |
| NCT06356779 |
Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease |
RECRUITING | NA |
